Update on controversy surrounding the drug, Epilim (Sodium Valproate) and the risks associated with taking this drug while pregnant.
Posted in News on Thursday, August 30th, 2018
Cantillons Solicitors have been receiving queries from women who were prescribed the anti-convulsant drug Epilim (Sodium Valproate) during pregnancy with concerns over the link between the drug and fetal anti-convulsant syndrome. The Health Service Executive Valproate Response Group indicated in May 2018, that they will be contacting women who were prescribed this drug during pregnancy “in the coming weeks”, (despite knowing about the risks associated with the drug since 2014). However, as far as we are aware, to date, no women have been contacted by the Health Service Executive notifying them of risks. We are continuing to investigate the matter on behalf of our clients and are awaiting the Health Service Executives plan of action with regards to notification of the affected women and the procedures that will need to be in place for patients to be reviewed by specialist teams. However, we have advised our clients that irrespective of what the Health Service Executive do or do not do, there are strict time limits that apply to these potential claims and those affected should seek legal advice urgently.
Contact us at Cantillons Solicitors at +353(0)214275673 or email@example.com if you would like more information.
“In contentious business, a solicitor may not calculate fees or other charges as a percentage or proportion of any award or settlement.”